KR102688003B1 - 단백질 peg화에 사용하기 위한 첨가제 시스템 - Google Patents

단백질 peg화에 사용하기 위한 첨가제 시스템 Download PDF

Info

Publication number
KR102688003B1
KR102688003B1 KR1020187017508A KR20187017508A KR102688003B1 KR 102688003 B1 KR102688003 B1 KR 102688003B1 KR 1020187017508 A KR1020187017508 A KR 1020187017508A KR 20187017508 A KR20187017508 A KR 20187017508A KR 102688003 B1 KR102688003 B1 KR 102688003B1
Authority
KR
South Korea
Prior art keywords
protein
pegylation
reaction
peg
additive system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187017508A
Other languages
English (en)
Korean (ko)
Other versions
KR20180081610A (ko
Inventor
매튜 알. 히키
안토니오 라미레즈
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20180081610A publication Critical patent/KR20180081610A/ko
Application granted granted Critical
Publication of KR102688003B1 publication Critical patent/KR102688003B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020187017508A 2015-11-23 2016-11-22 단백질 peg화에 사용하기 위한 첨가제 시스템 Active KR102688003B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562258644P 2015-11-23 2015-11-23
US62/258,644 2015-11-23
PCT/US2016/063313 WO2017091568A1 (en) 2015-11-23 2016-11-22 Additive systems for use in protein pegylation

Publications (2)

Publication Number Publication Date
KR20180081610A KR20180081610A (ko) 2018-07-16
KR102688003B1 true KR102688003B1 (ko) 2024-07-23

Family

ID=57589163

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187017508A Active KR102688003B1 (ko) 2015-11-23 2016-11-22 단백질 peg화에 사용하기 위한 첨가제 시스템

Country Status (17)

Country Link
US (3) US10617765B2 (https=)
EP (2) EP3789395B1 (https=)
JP (2) JP6921821B2 (https=)
KR (1) KR102688003B1 (https=)
CN (2) CN115819494A (https=)
CY (1) CY1123699T1 (https=)
DK (1) DK3380487T3 (https=)
ES (2) ES3055983T3 (https=)
HR (1) HRP20201832T1 (https=)
HU (1) HUE052634T2 (https=)
LT (1) LT3380487T (https=)
PL (1) PL3380487T3 (https=)
PT (1) PT3380487T (https=)
RS (1) RS61072B1 (https=)
SI (1) SI3380487T1 (https=)
SM (1) SMT202000649T1 (https=)
WO (1) WO2017091568A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3380487T (pt) * 2015-11-23 2020-10-29 Bristol Myers Squibb Co Sistemas de aditivos para utilização na peguilação de proteínas
HRP20240016T1 (hr) * 2018-09-11 2024-03-29 Ambrx, Inc. Konjugati polipeptida interleukina-2 i njihove uporabe
CN111484551B (zh) * 2020-03-19 2022-02-11 北京翼方生物科技有限责任公司 一种聚乙二醇修饰的重组人碱性成纤维细胞生长因子

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056448A2 (en) 2005-11-08 2007-05-18 Ambrx, Inc. Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19535571A1 (de) 1995-09-14 1997-03-20 Boehringer Mannheim Gmbh Pharmazeutische Kombinationspräparate und deren Verwendung zur Behandlung von Hämodialysepatienten
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
EP0885613A1 (de) 1997-06-21 1998-12-23 Roche Diagnostics GmbH Verwendung von modifizierten Hämoglobinen zur Behandlung von Anämien und Kombinationspräparate umfassend Erythropoietin und modifiziertes Hämoglobin
DE19734293A1 (de) 1997-08-08 1999-02-11 Boehringer Mannheim Gmbh Verwendung von pharmazeutischen Kombinationspräparaten enthaltend Erythropoietin und Eisenpräparate zur Behandlung von rheumatischen Erkrankungen
US7329516B2 (en) * 2004-03-17 2008-02-12 Anticancer, Inc. Methods for increasing protein polyethylene glycol (PEG) conjugation
US20060286657A1 (en) * 2005-06-01 2006-12-21 Samuel Zalipsky Novel bioconjugation reactions for acylating polyethylene glycol reagents
CA2682147C (en) * 2007-03-30 2017-08-08 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
AU2014212308B2 (en) 2013-01-30 2018-08-09 Avelas Biosciences, Inc. Selective delivery molecules and methods of use
WO2014176284A1 (en) 2013-04-22 2014-10-30 Avelas Biosciences, Inc. Selective drug delivery compositions and methods of use
SMT202100388T1 (it) 2014-10-24 2021-09-14 Bristol Myers Squibb Co Polipeptidi fgf-21 modificati e loro usi
PT3380487T (pt) * 2015-11-23 2020-10-29 Bristol Myers Squibb Co Sistemas de aditivos para utilização na peguilação de proteínas

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056448A2 (en) 2005-11-08 2007-05-18 Ambrx, Inc. Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
JP2009515881A (ja) 2005-11-08 2009-04-16 アンブルックス，インコーポレイテッド 非天然アミノ酸、および非天然アミノ酸ポリペプチドを修飾するための促進剤

Also Published As

Publication number Publication date
ES2827776T3 (es) 2021-05-24
EP3789395A1 (en) 2021-03-10
JP7257457B2 (ja) 2023-04-13
RS61072B1 (sr) 2020-12-31
PT3380487T (pt) 2020-10-29
US11213589B2 (en) 2022-01-04
SI3380487T1 (sl) 2020-11-30
HRP20201832T1 (hr) 2021-01-08
LT3380487T (lt) 2020-12-28
WO2017091568A1 (en) 2017-06-01
US20190351065A1 (en) 2019-11-21
CN108350025B (zh) 2023-02-21
US20220160883A1 (en) 2022-05-26
ES3055983T3 (en) 2026-02-17
WO2017091568A8 (en) 2018-01-04
EP3380487A1 (en) 2018-10-03
JP2019503994A (ja) 2019-02-14
PL3380487T3 (pl) 2020-12-28
HUE052634T2 (hu) 2021-05-28
EP3380487B1 (en) 2020-09-02
US20200276319A1 (en) 2020-09-03
CY1123699T1 (el) 2022-03-24
JP6921821B2 (ja) 2021-08-18
CN115819494A (zh) 2023-03-21
EP3789395B1 (en) 2025-08-27
US10617765B2 (en) 2020-04-14
JP2021176890A (ja) 2021-11-11
KR20180081610A (ko) 2018-07-16
SMT202000649T1 (it) 2021-01-05
CN108350025A (zh) 2018-07-31
DK3380487T3 (da) 2020-12-07

Similar Documents

Publication Publication Date Title
Vesely et al. Organocatalytic Enantioselective Aziridination of α, β‐Unsaturated Aldehydes
US20220160883A1 (en) Additive systems for use in protein pegylation
Lancaster et al. Aromatic nitrations in ionic liquids: the importance of cation choice
Van Emelen et al. C–N coupling reactions with arenes through C–H activation: the state-of-the-art versus the principles of green chemistry
JP4803352B2 (ja) アミノ酸−ｎ−カルボキシ無水物の製造方法
Guthrie et al. Ketoxime peptide ligations: oxidative couplings of alkoxyamines to N-aryl peptides
KR102593038B1 (ko) 알킬아민 유도체의 제조 방법 및 이의 제조 중간체
Arrigoni et al. Morpholine Prevents the Formation of Aspartimide from β-allyl ester aspartic acid during Fmoc Cleavage in SPPS of Stapled Peptides
Valeur et al. PS-IIDQ: an efficient polymer-supported amide coupling reagent
Byun et al. Preparation of polymer-bound pyrazolone active esters for combinatorial chemistry
KR101692992B1 (ko) 고리형 펩타이드의 사전 활성화 합성방법 및 이에 따라 합성된 고리형 펩타이드
US20240319146A1 (en) Analysis method for peptide bound to carrier for liquid phase peptide synthesis
Neo et al. Allylic amination of Passerini adducts. Application to the selective synthesis of chromone-substituted α-and γ-amino acid peptidic and retropeptidic units
JP5217545B2 (ja) アミノ酸−ｎ−カルボキシ無水物の製造法
Hoan Synthesis and biological activity evaluation of some derivatives synthesized from curcumin and curcumin analog
Lee et al. Phase-transfer catalytic aza-Michael addition of tert-butyl benzyloxycarbamate to electron-deficient olefins
CN117658866A (zh) 一种叠氮氨基酸衍生物的合成方法
Méret Development of an efficient and flexible method for the solid-phase synthesis of N-hydroxypolyamine derivatives
Kelleher et al. Use of the Mitsunobu Reaction in the Synthesis of Orthogonally Protected a, b-Diaminopropionic Acids

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180620

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211118

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231128

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240711

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240719

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240719

End annual number: 3

Start annual number: 1

PG1601 Publication of registration